{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:31:54Z","timestamp":1740123114471,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T00:00:00Z","timestamp":1731801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T00:00:00Z","timestamp":1731801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004621","name":"Kerman University of Medical Sciences","doi-asserted-by":"crossref","award":["98000844"],"award-info":[{"award-number":["98000844"]}],"id":[{"id":"10.13039\/501100004621","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11033-024-10074-x","type":"journal-article","created":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T03:12:41Z","timestamp":1731813161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhanced induction of apoptosis in chronic myeloid leukemia cells through synergistic effect of telomerase inhibitor MST-312 and imatinib"],"prefix":"10.1007","volume":"51","author":[{"given":"Najibe","family":"Karami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir Abbas","family":"Navidinia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Ehsan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Farsinejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9869-0147","authenticated-orcid":false,"given":"Ahmad","family":"Fatemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,17]]},"reference":[{"issue":"22","key":"10074_CR1","doi-asserted-by":"publisher","first-page":"5822","DOI":"10.3390\/cancers13225822","volume":"13","author":"K Ito","year":"2021","unstructured":"Ito K, Ito K (2021) Leukemia stem cells as a potential target to achieve therapy-free remission in chronic myeloid leukemia. Cancers 13(22):5822","journal-title":"Cancers"},{"issue":"1","key":"10074_CR2","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41392-022-01290-7","volume":"8","author":"Q Qiu","year":"2023","unstructured":"Qiu Q, Sun Y, Yang L, Li Q, Feng Y, Li M et al (2023) TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTEN. Signal Transduct Target Ther 8(1):90","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10074_CR3","doi-asserted-by":"publisher","first-page":"17990","DOI":"10.1038\/s41598-022-21009-6","volume":"12","author":"W Liu","year":"2022","unstructured":"Liu W, Zhu X, Tang L, Shen N, Cheng F, Zou P et al (2022) ACSL1 promotes imatinib-induced chronic myeloid leukemia cell senescence by regulating SIRT1\/p53\/p21 pathway. Sci Rep 12(1):17990","journal-title":"Sci Rep"},{"issue":"2","key":"10074_CR4","first-page":"114","volume":"15","author":"A Amouei","year":"2021","unstructured":"Amouei A, Daeian N, Khezrnia SS, Mansouri A, Hadjibabaie M (2021) Imatinib efficacy, safety and resistance in iranian patients with chronic myeloid leukemia: a review of literature. Int J Hematol Oncol Stem Cell Res 15(2):114","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"issue":"3","key":"10074_CR5","doi-asserted-by":"publisher","first-page":"869","DOI":"10.21873\/invivo.11552","volume":"33","author":"C Smeding","year":"2019","unstructured":"Smeding C, Szyd\u0142o A, Pieluszczak K, Grzeszkiewicz K, Pawelec K (2019) Efficacy and safety of Imatinib in Paediatric CML\u2013a single centre study. In Vivo 33(3):869\u2013875","journal-title":"In Vivo"},{"key":"10074_CR6","unstructured":"Tauchi T, Nakajima A, Sashida G, Shimamoto T, Ohyashiki JH, Abe K et al (2002) Inhibition of Human Telomerase Enhances the Effect of the Tyrosine Kinase Inhibitor, Imatinib, in BCR-ABL-positive Leukemia Cells. Clinical cancer research 8(11):3341\u20133347"},{"issue":"1","key":"10074_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3390\/metabo13010058","volume":"13","author":"E Bilajac","year":"2022","unstructured":"Bilajac E, Mahmutovi\u0107 L, Glamo\u010dlija U, Osmanovi\u0107 A, Hromi\u0107-Jahjefendi\u0107 A, Tambuwala MM, Suljagi\u0107 M (2022) Curcumin decreases viability and inhibits proliferation of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cell lines. Metabolites 13(1):58","journal-title":"Metabolites"},{"issue":"1","key":"10074_CR8","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1186\/s12885-018-4633-x","volume":"18","author":"P Solomon","year":"2018","unstructured":"Solomon P, Dong Y, Dogra S, Gupta R (2018) Interleukin 8 is a biomarker of telomerase inhibition in cancer cells. BMC Cancer 18(1):730","journal-title":"BMC Cancer"},{"issue":"12","key":"10074_CR9","doi-asserted-by":"publisher","first-page":"9817","DOI":"10.1002\/jcb.27301","volume":"119","author":"C Biray Avci","year":"2018","unstructured":"Biray Avci C, Dogan F, Ozates Ay NP, Goker Bagca B, Abbaszadeh Z, Gunduz C (2018) Effects of telomerase inhibitor on epigenetic chromatin modification enzymes in malignancies. J Cell Biochem 119(12):9817\u20139824","journal-title":"J Cell Biochem"},{"key":"10074_CR10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/978-1-4939-9666-7_21","volume-title":"G-Quadruplex Nucleic Acids","author":"F Pu","year":"2019","unstructured":"Pu F, Ren J, Qu X (2019) Primer-Modified G-Quadruplex-Au nanoparticles for colorimetric assay of human telomerase activity and initial screening of telomerase inhibitors. G-Quadruplex Nucleic Acids. Springer, New York, pp 347\u2013356"},{"issue":"5","key":"10074_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1158\/1535-7163.MCT-10-0979","volume":"10","author":"L Deville","year":"2011","unstructured":"Deville L, Hillion J, Pendino F, Samy M, Nguyen E, S\u00e9gal-Bendirdjian E (2011) hTERT promotes imatinib resistance in chronic myeloid leukemia cells: therapeutic implications. Mol Cancer Ther 10(5):711\u2013719","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10074_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hon.901","volume":"27","author":"G Keller","year":"2009","unstructured":"Keller G, Brassat U, Braig M, Heim D, Wege H, Br\u00fcmmendorf TH (2009) Telomeres and telomerase in chronic myeloid leukaemia: impact for pathogenesis, disease progression and targeted therapy. Hematol Oncol 27(3):123\u2013129","journal-title":"Hematol Oncol"},{"issue":"9","key":"10074_CR13","first-page":"657","volume":"1","author":"H Seimiya","year":"2002","unstructured":"Seimiya H, Oh-hara T, Suzuki T, Naasani I, Shimazaki T, Tsuchiya K, Tsuruo T (2002) Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-199. Mol Cancer Ther 1(9):657\u2013665","journal-title":"Mol Cancer Ther"},{"key":"10074_CR14","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.biopha.2018.07.140","volume":"106","author":"N Ghasemimehr","year":"2018","unstructured":"Ghasemimehr N, Farsinejad A, Khalilabadi RM, Yazdani Z, Fatemi A (2018) The telomerase inhibitor MST-312 synergistically enhances the apoptotic effect of doxorubicin in pre-B acute lymphoblastic leukemia cells. Biomed Pharmacother 106:1742\u20131750","journal-title":"Biomed Pharmacother"},{"issue":"4\u20136","key":"10074_CR15","first-page":"283","volume":"7","author":"RL Gurung","year":"2015","unstructured":"Gurung RL, Lim SN, Low GKM, Hande MP (2015) MST-312 alters telomere dynamics, gene expression profiles and growth in human breast cancer cells. J Nutrigenet Nutrigenomics 7(4\u20136):283\u2013298","journal-title":"J Nutrigenet Nutrigenomics"},{"key":"10074_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.lfs.2019.04.060","volume":"228","author":"Z Ameri","year":"2019","unstructured":"Ameri Z, Ghiasi S, Farsinejad A, Hassanshahi G, Ehsan M, Fatemi A (2019) Telomerase inhibitor MST-312 induces apoptosis of multiple myeloma cells and down-regulation of anti-apoptotic, proliferative and inflammatory genes. Life Sci 228:66\u201371","journal-title":"Life Sci"},{"key":"10074_CR17","doi-asserted-by":"publisher","first-page":"8425","DOI":"10.1007\/s13277-015-3575-z","volume":"36","author":"A Fatemi","year":"2015","unstructured":"Fatemi A, Safa M, Kazemi A (2015) MST-312 induces G2\/M cell cycle arrest and apoptosis in APL cells through inhibition of telomerase activity and suppression of NF-\u03baB pathway. Tumor Biology 36:8425\u20138437","journal-title":"Tumor Biology"},{"key":"10074_CR18","unstructured":"Viswanathan R, Sameni S, Ng GY-Q, Martinez-Lopez W, Hande P (2023) Telomerase inhibition by MST-312 sensitises breast cancer cells to anti-cancer properties of Plumbagin. BioRxiv 2023.05. 29.542688"},{"issue":"1","key":"10074_CR19","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3233\/TUB-211515","volume":"43","author":"TH Andrade da Mota","year":"2021","unstructured":"Andrade da Mota TH, Reis Guimar\u00e3es AF, Silva de Carvalho A\u00c9, Saldanha-de Araujo F, Pinto de Faria Lopes G, Pittella-Silva F et al (2021) Effects of in vitro short-and long-term treatment with telomerase inhibitor in U-251 glioma cells. Tumor Biol 43(1):327\u2013340","journal-title":"Tumor Biol"},{"issue":"5","key":"10074_CR20","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3390\/jpm11050332","volume":"11","author":"S-J Wang","year":"2021","unstructured":"Wang S-J, Yang P-M (2021) A bioinformatics analysis identifies the telomerase inhibitor MST-312 for treating high-STMN1-expressing hepatocellular carcinoma. J Pers Med 11(5):332","journal-title":"J Pers Med"},{"issue":"9","key":"10074_CR21","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/cbin.11843","volume":"46","author":"NJ Villarinho","year":"2022","unstructured":"Villarinho NJ, Vasconcelos FDC, Mazzoccoli L, da Silva Robaina MC, Pessoa LS, Siqueira PET et al (2022) Effects of long-term exposure to MST-312 on lung cancer cells tumorigenesis: role of SHH\/GLI-1 axis. Cell Biol Int 46(9):1468\u20131479","journal-title":"Cell Biol Int"},{"issue":"4","key":"10074_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.14715\/cmb\/2021.67.4.13","volume":"67","author":"C Zhou","year":"2021","unstructured":"Zhou C, Liu S (2021) Evaluation of the efficacy of MST-312, as a telomerase inhibitor, in the treatment of patients with multiple myeloma after stem cell transplantation. Cell Mol Biol (Noisy-le-grand) 67(4):115\u2013120","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"issue":"9","key":"10074_CR23","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.3324\/haematol.2020.252817","volume":"106","author":"EO Leibundgut","year":"2021","unstructured":"Leibundgut EO, Haubitz M, Burington B, Ottmann OG, Spitzer G, Odenike O et al (2021) Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat. Haematologica 106(9):2397","journal-title":"Haematologica"},{"issue":"1","key":"10074_CR24","first-page":"260","volume":"43","author":"W Ma","year":"2020","unstructured":"Ma W, Liu F, Yuan L, Zhao C, Chen C (2020) Emodin and AZT synergistically inhibit the proliferation and induce the apoptosis of leukemia K562 cells through the EGR1 and the Wnt\/\u03b2-catenin pathway. Oncol Rep 43(1):260\u2013269","journal-title":"Oncol Rep"},{"issue":"1","key":"10074_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12964-022-01021-z","volume":"20","author":"F Zeng","year":"2022","unstructured":"Zeng F, Peng Y, Qin Y, Wang J, Jiang G, Feng W, Yuan Y (2022) Wee1 promotes cell proliferation and imatinib resistance in chronic myeloid leukemia via regulating DNA damage repair dependent on ATM-\u03b3H2AX-MDC1. Cell Commun Signal 20(1):199","journal-title":"Cell Commun Signal"},{"issue":"5","key":"10074_CR26","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.exphem.2005.02.002","volume":"33","author":"U Hartmann","year":"2005","unstructured":"Hartmann U, Balabanov S, Ziegler P, Fellenberg J, van der Kuip H, Duyster J et al (2005) Telomere length and telomerase activity in the BCR-ABL-transformed murine Pro-B cell line BaF3 is unaffected by treatment with imatinib. Exp Hematol 33(5):542\u2013549","journal-title":"Exp Hematol"},{"issue":"3","key":"10074_CR27","doi-asserted-by":"publisher","first-page":"261","DOI":"10.18632\/oncotarget.461","volume":"3","author":"C Vicente-Due\u00f1as","year":"2012","unstructured":"Vicente-Due\u00f1as C, Barajas-Diego M, Romero-Camarero I, Gonz\u00e1lez-Herrero I, Flores T, S\u00e1nchez-Garc\u00eda I (2012) Essential role for telomerase in chronic myeloid leukemia induced by BCR-ABL in mice. Oncotarget 3(3):261","journal-title":"Oncotarget"},{"key":"10074_CR28","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1134\/S0006297910130055","volume":"75","author":"M Zvereva","year":"2010","unstructured":"Zvereva M, Shcherbakova D, Dontsova O (2010) Telomerase: structure, functions, and activity regulation. Biochem Mosc 75:1563\u20131583","journal-title":"Biochem Mosc"},{"issue":"12","key":"10074_CR29","doi-asserted-by":"publisher","first-page":"a032383","DOI":"10.1101\/cshperspect.a032383","volume":"11","author":"Y Wang","year":"2019","unstructured":"Wang Y, Su\u0161ac L, Feigon J (2019) Structural biology of telomerase. Cold Spring Harb Perspect Biol 11(12):a032383","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10074_CR30","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s11523-015-0364-y","volume":"10","author":"Y Shi","year":"2015","unstructured":"Shi Y, Sun L, Chen G, Zheng D, Li L, Wei W (2015) A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines. Target Oncol 10:565\u2013573","journal-title":"Target Oncol"},{"key":"10074_CR31","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10549-015-3270-1","volume":"149","author":"JE Koziel","year":"2015","unstructured":"Koziel JE, Herbert B-S (2015) The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells. Breast Cancer Res Treat 149:607\u2013618","journal-title":"Breast Cancer Res Treat"},{"issue":"1\u20132","key":"10074_CR32","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0014-5793(04)00318-7","volume":"564","author":"R Bakalova","year":"2004","unstructured":"Bakalova R, Ohba H, Zhelev Z, Kubo T, Fujii M, Ishikawa M et al (2004) Antisense inhibition of Bcr-Abl\/c-Abl synthesis promotes telomerase activity and upregulates tankyrase in human leukemia cells1. FEBS Lett 564(1\u20132):73\u201384","journal-title":"FEBS Lett"},{"key":"10074_CR33","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.canlet.2019.11.017","volume":"469","author":"C Grandjenette","year":"2020","unstructured":"Grandjenette C, Schnekenburger M, Gaigneaux A, Gerard D, Christov C, Mazumder A et al (2020) Human telomerase reverse transcriptase depletion potentiates the growth-inhibitory activity of imatinib in chronic myeloid leukemia stem cells. Cancer Lett 469:468\u2013480","journal-title":"Cancer Lett"},{"issue":"5","key":"10074_CR34","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1172\/JCI79134","volume":"125","author":"CM Koh","year":"2015","unstructured":"Koh CM, Khattar E, Leow SC, Liu CY, Muller J, Ang WX et al (2015) Telomerase regulates MYC-driven oncogenesis independent of its reverse transcriptase activity. J Clin Investig 125(5):2109\u20132122","journal-title":"J Clin Investig"},{"issue":"7251","key":"10074_CR35","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/nature08137","volume":"460","author":"J-I Park","year":"2009","unstructured":"Park J-I, Venteicher AS, Hong JY, Choi J, Jun S, Shkreli M et al (2009) Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 460(7251):66\u201372","journal-title":"Nature"},{"issue":"3","key":"10074_CR36","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.18632\/oncotarget.23283","volume":"9","author":"G Sodaro","year":"2018","unstructured":"Sodaro G, Cesaro E, Montano G, Blasio G, Fiorentino F, Romano S et al (2018) Role of ZNF224 in c-Myc repression and imatinib responsiveness in chronic myeloid leukemia. Oncotarget 9(3):3417","journal-title":"Oncotarget"},{"issue":"5","key":"10074_CR37","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1158\/1541-7786.MCR-10-0356","volume":"9","author":"M Albajar","year":"2011","unstructured":"Albajar M, G\u00f3mez-Casares MT, Llorca J, Mauleon I, Vaqu\u00e9 JP, Acosta JC et al (2011) MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib. Mol Cancer Res 9(5):564\u2013576","journal-title":"Mol Cancer Res"},{"issue":"6","key":"10074_CR38","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1080\/10245332.2016.1275426","volume":"22","author":"D Bashash","year":"2017","unstructured":"Bashash D, Zareii M, Safaroghli-Azar A, Omrani MD, Ghaffari SH (2017) Inhibition of telomerase using BIBR1532 enhances doxorubicin-induced apoptosis in pre-B acute lymphoblastic leukemia cells. Hematology 22(6):330\u2013340","journal-title":"Hematology"},{"key":"10074_CR39","doi-asserted-by":"publisher","first-page":"1027441","DOI":"10.3389\/fphar.2022.1027441","volume":"13","author":"W-J Zhong","year":"2022","unstructured":"Zhong W-J, Ma L, Yang F, Cao J, Tan J, Li B (2022) Matrine, a potential c-Myc inhibitor, suppresses ribosome biogenesis and nucleotide metabolism in myeloid leukemia. Front Pharmacol 13:1027441","journal-title":"Front Pharmacol"},{"issue":"12","key":"10074_CR40","doi-asserted-by":"publisher","first-page":"10323","DOI":"10.1074\/jbc.M106607200","volume":"277","author":"N-S Chang","year":"2002","unstructured":"Chang N-S (2002) The non-ankyrin C terminus of I\u03baB\u03b1 physically interacts with p53 in vivo and dissociates in response to apoptotic stress, hypoxia, DNA damage, and transforming growth factor-\u03b21-mediated growth suppression. J Biol Chem 277(12):10323\u201310331","journal-title":"J Biol Chem"},{"issue":"1","key":"10074_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2172-6-12","volume":"6","author":"DH Dreyfus","year":"2005","unstructured":"Dreyfus DH, Nagasawa M, Gelfand EW, Ghoda LY (2005) Modulation of p53 activity by I\u03baB\u03b1: evidence suggesting a common phylogeny between NF-\u03baB and p53 transcription factors. BMC Immunol 6(1):1\u201319","journal-title":"BMC Immunol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-10074-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-024-10074-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-10074-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T04:48:52Z","timestamp":1738730932000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-024-10074-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,17]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10074"],"URL":"https:\/\/doi.org\/10.1007\/s11033-024-10074-x","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"type":"print","value":"0301-4851"},{"type":"electronic","value":"1573-4978"}],"subject":[],"published":{"date-parts":[[2024,11,17]]},"assertion":[{"value":"26 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study gained the approval of the ethical committee of Kerman University of Medical Sciences with the Ethics approval code of IR.KMU.REC.1398.611.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"1161"}}